Inflazome Ltd.

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. BMS Calls On SyntheX, Autolus In Protei

Zydus Lifesciences Limited recently announced achieving positive proof of concept in a Phase II clinical study of its NLRP3 inflammasome inhibitor ZYIL1 to treat cryopyrin-associated periodic syndrom

Roche Holding AG , Genentech, Inc. and their affiliated companies were the busiest deal makers in the biopharmaceutical sector for the second consecutive year in 2021, with 23 deals across all cate

A new UK infectious diseases company,Poolbeg Pharma plc , is being spun out of the CRO, Open Orphan plc and, with a completed fund-raising, is planning to pursue a capital-light clinical model to dev